Carregant...
Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists
Therapeutic agents for refractory prolactinomas that are resistant to dopamine agonists (DAs) are troublesome, and surgery often only removes a large part of the tumor without complete remission. Among the various second-line treatment regimens, the treatment effect of the alkylating agent temozolom...
Guardat en:
| Publicat a: | Front Endocrinol (Lausanne) |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7996095/ https://ncbi.nlm.nih.gov/pubmed/33776913 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2021.616339 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|